Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu
Help guide our efforts to modernize ClinicalTrials.gov.
Send us your comments by March 14, 2020.
Trial record 1 of 87 for:    Breast cancer diet
Previous Study | Return to List | Next Study

Breast Cancer Diet Intervention Study (BCDIS)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03886389
Recruitment Status : Completed
First Posted : March 22, 2019
Last Update Posted : May 13, 2019
Sponsor:
Information provided by (Responsible Party):
Haavard Soiland, Helse Stavanger HF

Brief Summary:

The investigators have already proven that Mitotic Activity Index (MAI)is the most robust measure of proliferation in breast cancer tissue.

The purpose was to study whether 18 and 2-4 hours pre-operative per-oral carbohydrate loading (often given in gastrointestinal surgery i.e. enhanced recovery after surgery=ERAS) influences proliferation in the tumor, serum insulin characteristics, metabolic profile and survival.


Condition or disease Intervention/treatment Phase
Early-stage Breast Cancer Carbohydrate Engorgement Proliferation Insulin Resistance Estrogen Receptor-positive Breast Cancer Dietary Supplement: PreOP Not Applicable

Detailed Description:

It has been postulated that a "Western-style" diet, rich in carbohydrates (especially high glycemic carbohydrates) may have an effect on the incidence of breast cancer, and perhaps also prognosis. This may be mediated through the insulin-related pathways in breast cells which may show insulin-dependent proliferation, which may alter outcome.

Aims:

To study:

  1. The inter-patient variation in insulin and insulin-related characteristics in the blood taken just before the operation from breast cancer patients, on a usual pre-operative fasting schedule;
  2. The influence of the variation in insulin and insulin-related characteristics on proliferation and other cell biological features in the breast cancers of these patients;
  3. Whether 4 and 18-hours pre-operative hyperglycaemic glucose loading (to reduce postoperative insulin resistance) influences proliferation (Mitotic Activity Index (MAI) and other cell biological features in breast cancer*
  4. The influence of the short-term effect of a pre-operative low-glycaemic carbohydrate isocaloric diet on proliferation and other cell biological features of the primary breast cancer cells (Low-glycemic isocaloric diet intervention study);
  5. Epidemiological risk factors: The correlation between epidemiological risk factors, insulin and insulin-related characteristics, proliferation, cell biological features and other biomarkers in breast cancer patients.
  6. Estrogen Receptor positive tumors will be analyses separately.
  7. Relapse free survival
  8. Breast Cancer Specific Survival.

The Short-term effect of carbohydrates will be assessed in a randomized intervention study, where 30 patients receive oral carbohydrates 18 and 4 hours before surgery and 30 patients receive fasting procedure/water.

Primary Outcome

1. Proliferation in the tumor as measured by MAI.

Secondary Outcomes:

  1. Serum insulin characteristics (S-insulin, S- insulin c-peptide, S-IGF and S-IGFBP3) will be measured at various peri-surgical timepoints
  2. Changes in metabolic profile* in the tumor and in serum samples
  3. Patient Reported Outcome Measures (PROM) on well being
  4. Relapse free survival
  5. Breast Cancer Specific Survival

    • Metabolic profile assessed by High Resolution Magnetic Resonance Spectroscopy (HR-MRS) in the tumor and in serum samples.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 80 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Intervention Model Description: Allocation: Randomized Intervention Model: Parallel Assignment Masking: None (Open Label) Primary Purpose: Treatment
Masking: None (Open Label)
Primary Purpose: Basic Science
Official Title: The Effects of Insulin and Insulin-related Characteristics, and Short-Term Low-glycemic and High-glycemic Carbohydrate Intervention on Breast Cancer Biomarkers and Survival
Actual Study Start Date : June 12, 2009
Actual Primary Completion Date : July 7, 2017
Actual Study Completion Date : July 7, 2017

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Breast Cancer

Arm Intervention/treatment
Experimental: Carbohydrate/intervention group
Breast cancer patients receive 2 x preoperative carbohydrate loading [PreOP(TM)] before surgery; the 1st dose 18 hours before and 2nd dose 2-4 hours before surgery.
Dietary Supplement: PreOP
Mixture of Carbohydrates; standard amount designed for enhanced recovery after surgery (ERAS) i.e. preoperative carbohydrate loading before long standing surgery to enhance recovery.

No Intervention: Control group
Breast cancer patients receive standard prep fasting procedure with nil food per os 8-10 hours before surgery, drinking tap water until 2 hours before surgery.



Primary Outcome Measures :
  1. Mitotic Activity Index (MAI) [ Time Frame: Trough completion of surgery of all included patients, an average of 1,5 years ]
    Proliferation in invasive front in tumor


Secondary Outcome Measures :
  1. S-Insulin [ Time Frame: Analysed in serum samples at 5 time points; At inclusion (day 0), admission (day 10), preoperatively (day 11), postoperatively (day12) and at post operative visit (day 30) ]
    Secretion of insulin into serum; unit, mIE/L (milli international units pr liter)

  2. Well being after surgery [ Time Frame: Day 1,2,3,4,5,6 and 7 after surgery ]
    Patient Reported Outcome Measures (Questionaire)

  3. High Resolution Magnetic Resonance Spectroscopy (HR-MRS) profiling of specific metabolites [ Time Frame: Immediately after surgery: tumor is fresh frozen. High Resolution Magnetic Resonance Spectroscopy (HR-MRS) will be done in the fresh frozen tumor and deep frozen serum samples (=as for insulin characteristics) ]
    Metabolic profiling in the primary tumor and in the serum samples; measure content of lactate, glycine, choline, fatty acids and lipoproteins

  4. Relapse Free Survival [ Time Frame: Until 8 years (97 months of follow up) ]
    Time from surgery to a relapse (Loco-regional, contralateral and systemic) is experienced

  5. Breast Cancer Specific Survival [ Time Frame: 8 years follow-up (97 months of follow up) ]
    Time from surgery to dead of disease or all other causes of death.

  6. S-insulin c-peptide, [ Time Frame: Analysed in serum samples at 5 time points; At inclusion (day 0), admission (day 10), preoperatively (day 11), postoperatively (day12) and at post operative visit (day 30) ]
    Measure of total insulin secreted; unit, nM (nano molar)

  7. S-IGF1 [ Time Frame: Analysed in serum samples at 5 time points; At inclusion (day 0), admission (day 10), preoperatively (day 11), postoperatively (day12) and at post operative visit (day 30) ]
    Measure of Insulin growth factor type 1; unit, nM (nano molar)

  8. S-IGFBP3 [ Time Frame: Analysed in serum samples at 5 time points; At inclusion (day 0), admission (day 10), preoperatively (day 11), postoperatively (day12) and at post operative visit (day 30) ]
    Measure of Insulin growth factor binding protein 3; unit mg/L (milligram per liter)

  9. PR [ Time Frame: Trough completion of surgery of all included patients, an average of 1,5 years ]
    Expression of Progesteron Receptor in the primary tumor



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   25 Years to 100 Years   (Adult, Older Adult)
Sexes Eligible for Study:   Female
Gender Based Eligibility:   Yes
Gender Eligibility Description:   Breast cancer is 100 x more frequent in women than in men.
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • All consecutive operable patients in 2009-2010, with a clinical and/or radiologic and/or cytologic diagnosis of primary breast cancer, unless the exclusion criteria apply.

Exclusion Criteria:

  1. Non-operable patients (i.e" patients with T3-4 (>5 cm) disease or distant metastases at the time of operation).
  2. All patients who refuse to participate.
  3. All patients with DCIS, micro-invasive cancer < 2mm diameter or tumors with histologic poor-quality material.
  4. Co-morbidity (Insulin dependent Diabetes Mellitus, Cushing syndrome, previous or concurrent cancers except CIN and non-melanomatous skin cancer.
  5. Mental inability to participate.
  6. Persons allergic to one of the compounds in any of the two diets.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03886389


Sponsors and Collaborators
Helse Stavanger HF
Investigators
Layout table for investigator information
Study Director: Svein Skeie, PhD Helse Stavanger HF; Stavanger University Hospital

Publications:
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Layout table for additonal information
Responsible Party: Haavard Soiland, Professor PhD, Helse Stavanger HF
ClinicalTrials.gov Identifier: NCT03886389    
Other Study ID Numbers: 59
First Posted: March 22, 2019    Key Record Dates
Last Update Posted: May 13, 2019
Last Verified: May 2019
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No
Plan Description: All data will be available to all researches involved in the study included the statistician allocated to the study.

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by Haavard Soiland, Helse Stavanger HF:
Breast Cancer
Estrogen receptor positive
Proliferation
Insulin resistance
PROMs
NMRI
RFS
BCSS
Additional relevant MeSH terms:
Layout table for MeSH terms
Breast Neoplasms
Neoplasms by Site
Neoplasms
Breast Diseases
Insulin Resistance
Skin Diseases
Hyperinsulinism
Glucose Metabolism Disorders
Metabolic Diseases
Insulin
Hypoglycemic Agents
Physiological Effects of Drugs